Fig. 3.

RRSP halts tumor growth in a KRAS^WT TNBC xenograft in vivo. (A) Tumor growth curve of vehicle, RRSP-DT_B and RRSP*-DT_B–treated athymic nu/nu female mice bearing MDA-MB-436–derived tumors. Mice received 0.1 mg/kg of RRSP-DT_B and 0.1 mg/kg of RRSP*-DT_B every other day (weekends excluded) via i.p. injection. (B). Column scatter plots showing individual tumor volumes at the end of the treatment schedule for MDA-MB-436 xenografts. Horizontal dotted line indicates the average tumor volume (baseline) on the first day of treatment (140 mm³). Data are means ± SEM (n = 5 mice per group; *P < 0.05, **P < 0.01). (C) Representative images of MDA-MB-436 tumors at the experimental endpoint. (D) Representative images of immunoreactivity to total RAS in sections from MDA-MB-436 tumors and (E) corresponding quantification of DAB (3,3′-diaminobenzidine) optical density (**P < 0.01, ***P < 0.001, one-way ANOVA followed by Tukey’s multiple comparison test, n = 3). (Scale bar = 100 µM.)